Peter J. Halfmann,Shun Iida,Kiyoko Iwatsuki-Horimoto,Tadashi Maemura,Maki Kiso,Suzanne M. Scheaffer,Tamarand L. Darling,Astha Joshi,Samantha Loeber,Gagandeep Singh,Stephanie L. Foster,Baoling Ying,James Brett Case,Zhenlu Chong,Bradley Whitener,Juan Moliva,Katharine Floyd,Michiko Ujie,Noriko Nakajima,Mutsumi Ito,Ryan Wright,Ryuta Uraki,Prajakta Warang,Matthew Gagne,Rong Li,Yuko Sakai-Tagawa,Yanan Liu,Deanna Larson,Jorge E. Osorio,Juan P. Hernandez-Ortiz,Amy R. Henry,Karl Ciuoderis,Kelsey R. Florek,Mit Patel,Abby Odle,Lok-Yin Roy Wong,Allen C. Bateman,Zhongde Wang,Venkata-Viswanadh Edara,Zhenlu Chong,John Franks,Trushar Jeevan,Thomas Fabrizio,Jennifer DeBeauchamp,Lisa Kercher,Patrick Seiler,Ana Silvia Gonzalez-Reiche,Emilia Mia Sordillo,Lauren A. Chang,Harm van Bakel,Viviana Simon,Daniel C. Douek,Nancy J. Sullivan,Larissa B. Thackray,Hiroshi Ueki,Seiya Yamayoshi,Masaki Imai,Stanley Perlman,Richard J. Webby,Robert A. Seder,Mehul S. Suthar,Adolfo García-Sastre,Michael Schotsaert,Tadaki Suzuki,Adrianus C. M. Boon,Michael S. Diamond,Yoshihiro Kawaoka,B. Alburquerque,H. Alshammary,A. A. Amoako,S. Aslam,R. Banu,C. Cognigni,M. Espinoza-Moraga,K. Farrugia,A. van de Guchte,Z. Khalil,M. Laporte,I. Mena,A. E. Paniz-Mondolfi,J. Polanco,A. Rooker,L. A. Sominsky,

Abstract:Abstract The recent emergence of B.1.1.529, the Omicron variant 1,2 , has raised concerns of escape from protection by vaccines and therapeutic antibodies. A key test for potential countermeasures against B.1.1.529 is their activity in preclinical rodent models of respiratory tract disease. Here, using the collaborative network of the SARS-CoV-2 Assessment of Viral Evolution (SAVE) programme of the National Institute of Allergy and Infectious Diseases (NIAID), we evaluated the ability of several B.1.1.529 isolates to cause infection and disease in immunocompetent and human ACE2 (hACE2)-expressing mice and hamsters. Despite modelling data indicating that B.1.1.529 spike can bind more avidly to mouse ACE2 (refs. 3,4 ), we observed less infection by B.1.1.529 in 129, C57BL/6, BALB/c and K18-hACE2 transgenic mice than by previous SARS-CoV-2 variants, with limited weight loss and lower viral burden in the upper and lower respiratory tracts. In wild-type and hACE2 transgenic hamsters, lung infection, clinical disease and pathology with B.1.1.529 were also milder than with historical isolates or other SARS-CoV-2 variants of concern. Overall, experiments from the SAVE/NIAID network with several B.1.1.529 isolates demonstrate attenuated lung disease in rodents, which parallels preliminary human clinical data.

SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters